Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

BACKGROUND: We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer’s disease (AD). METHODS: This double-blind, p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Alzheimers Res Ther
Main Authors: Salloway, Stephen, Honigberg, Lee A., Cho, William, Ward, Michael, Friesenhahn, Michel, Brunstein, Flavia, Quartino, Angelica, Clayton, David, Mortensen, Deborah, Bittner, Tobias, Ho, Carole, Rabe, Christina, Schauer, Stephen P., Wildsmith, Kristin R., Fuji, Reina N., Suliman, Shehnaaz, Reiman, Eric M., Chen, Kewei, Paul, Robert
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6146627/
https://ncbi.nlm.nih.gov/pubmed/30231896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0424-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki